Phaseline

Targets › AOC3

AOC3 (Amine oxidase [copper-containing] 3): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Sep 2027.

Catalyzes the oxidative deamination of primary amines to the corresponding aldehydes with the concomitant production of hydrogen peroxide and ammonia. Has a preference for the primary monoamines methylamine and benzylamine. (UniProt, Q16853)

Open in Phaseline: the race on AOC3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
EccogeneECC0509
Semicarbazide sensitive amine oxidase (SSAO) inhibitor
AOC3Phase 2Metabolic Dysfunction-associated SteatohepatitisSep 2027

Conditions

Metabolic Dysfunction-associated Steatohepatitis (1)

Modalities

small molecule (1)

Companies

Eccogene (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.